US Executive Officer Management Changes SEC — June 29, 2026

29-06-2026

PEDEVCO CORP announced the mutual departure of Paul Pinkston as Chief Accounting Officer, effective June 23, 2026. The filing does not disclose any financial impact or replacement details.

• · Departure was mutual and effective June 23, 2026.
• · No successor or interim CAO was announced.
• · No compensatory arrangements or severance were disclosed.

29-06-2026

Inhibikase Therapeutics, Inc. filed an 8-K on June 29, 2026, reporting amendments to its Certificate of Incorporation to limit personal liability of directors and officers to the fullest extent permitted by Delaware law, and to expand indemnification rights. The amendments were approved by stockholders at the annual meeting and became effective June 26, 2026. No financial figures were disclosed in this filing.

• · The amendment to Article IX of the Certificate of Incorporation eliminates personal liability of directors and officers for monetary damages for breach of fiduciary duty, to the fullest extent permitted by the DGCL.
• · The amendment also provides mandatory indemnification for directors and officers, and permissive indemnification for other employees and agents.
• · The amendment does not eliminate or reduce the effect of Article IX for matters occurring prior to the amendment.
• · The filing was made under Items 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), and 5.07 (Submission of Matters to a Vote of Security Holders).

29-06-2026

Picard Medical, Inc. appointed Dr. Joe Xiao to its Board of Directors on June 23, 2026, with a term expiring at the 2026 annual meeting. Dr. Xiao will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees. No material transactions or arrangements were disclosed in connection with his appointment.

• · Dr. Xiao was appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
• · Dr. Xiao entered into the Company's standard indemnification agreement for directors.
• · Compensation will follow the non-employee director policy described in the proxy statement filed June 15, 2026.
• · No arrangements or understandings exist between Dr. Xiao and any other person regarding his selection.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.

29-06-2026

Genesco Inc. (NYSE: GCO) announced the appointment of Jonathan Collins as Senior Vice President, Finance and Chief Financial Officer, effective August 3, 2026. Collins brings over 30 years of financial leadership experience, including senior roles at Walmart and most recently as CFO of America’s Car‑Mart. Mimi E. Vaughn, who had served as interim CFO since March 2026, will remain Board Chair, President and CEO. The appointment is part of Genesco’s continued execution of its ‘Footwear First’ strategy.

• · Effective date of CFO appointment is August 3, 2026.
• · Mimi E. Vaughn served as interim CFO since March 2026.
• · Collins spent 13 years at Walmart (2012‑2025) in senior finance roles across Africa, Flipkart (India) and Canada.
• · Most recently he was CFO of America’s Car‑Mart (2025‑2026).
• · Collins is a Certified Public Accountant and holds multiple advanced degrees from University of Illinois, Western Governors University and Kennesaw State University.
• · Genesco operates more than 1,200 retail stores along with branded e‑commerce websites.

29-06-2026

Frontdoor, Inc. (FTDR) announced the expansion of its board to nine members and the election of Hilla Sferruzza, EVP and CFO of Meritage Homes (NYSE: MTH), as an independent director effective June 29, 2026. Sferruzza, a CPA with over 30 years of experience in public company finance, real estate, and accounting, will also serve on the Audit Committee. This appointment brings enhanced financial and real estate expertise to the board, with Sferruzza slated to stand for re-election at the 2027 annual meeting.

• · The board expanded to nine members unanimously.
• · Sferruzza is a Certified Public Accountant in Arizona and holds an Executive MBA from Washington State University and a BS in Business Administration from the University of Arizona.
• · She is a member of the Arizona State University W.P. Carey School of Business Dean’s Council and Finance Advisory Board.
• · Frontdoor handles approximately 3.8 million service requests annually for over 2.1 million members through a network of about 17,000 independent contractors.

29-06-2026

Seaport Entertainment Group Inc. announced that Lucy Fato stepped down as EVP, General Counsel and Corporate Secretary effective June 25, 2026, and will serve as an Advisor to the CEO through August 24, 2026. Her separation is treated as a termination without cause under her employment agreement, with severance benefits contingent on her continued service through the separation date. No financial terms or replacement were disclosed.

• · Transition Date: June 25, 2026
• · Separation Date: August 24, 2026
• · Ms. Fato will serve as Advisor to the President and CEO during the transition period
• · Separation is classified as termination 'without cause' under her employment agreement
• · Severance payments and benefits are subject to release requirements and continued service through the Separation Date
• · The Transition Agreement is filed as Exhibit 10.1 to the 8-K

29-06-2026

Fathom Holdings Inc. (FTHM) set compensation for two interim officers appointed June 16, 2026. Interim CEO Adam Rothstein receives $30,000 per month; Interim CFO Daniel Weinmann entered an employment agreement with a $300,000 annual base salary and a discretionary bonus target of up to 30% of base. Severance for Weinmann includes six months' base salary if terminated without cause or for good reason.

• · Rothstein's salary is $30,000 per month effective retroactively from June 16, 2026.
• · Weinmann's employment agreement includes a six-month severance of his then-current monthly base salary if terminated without cause or for good reason, subject to a release of claims.
• · No mention of Rothstein's bonus or severance terms.

29-06-2026

Synchrony Financial announced executive leadership changes to advance its digital growth, customer experience, and AI momentum. Carol Juel was named CEO of the Digital platform, succeeding Bart Schaller who is retiring after 35 years; Florin Arghirescu was promoted to CTO, and DJ Casto expanded his role to Chief People and Operations Officer. The changes reflect a strategic focus on digital-first partnerships, AI adoption, and operational excellence.

• · Synchrony is ranked #1 Best Company to Work For in the U.S. by Fortune and Great Place to Work.
• · The company serves tens of millions of consumers and supports hundreds of thousands of small and midsize businesses, including health and wellness providers.
• · Forward-looking statements are subject to risks detailed in the company's 10-K for the year ended December 31, 2025.

29-06-2026

SafeSpace Global Corp (SSGC) announced the resignation of board member William Benjamin Pope, effective June 22, 2026. The resignation was not due to any disagreement with the company's operations, policies, or practices. No financial figures or performance metrics were disclosed in this filing.

• · The resignation was effective immediately on June 22, 2026.
• · The filing was signed by CEO Scott M. Boruff on June 29, 2026.
• · No replacement director was announced in this filing.

29-06-2026

Immunic, Inc. held its 2026 annual meeting on June 29, 2026, where shareholders elected Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick as Class III directors and approved an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000 to a total of 8,644,887. The appointment of Baker Tilly as independent auditor for fiscal 2026 was also ratified. The company noted no emerging growth company status.

• · The Plan was originally adopted on June 14, 2019, and had previously been amended on June 28, 2023, March 4, 2024, and June 4, 2025.
• · The Company is a Delaware corporation with its common stock traded on Nasdaq under the symbol IMUX.
• · The Plan will expire on the earlier of the 10th anniversary of the Effective Date (June 14, 2019) or when all shares have been purchased or restrictions lapsed.

29-06-2026

Aimei Health Technology Co., Ltd. announced the resignation of director Julianne Huh effective June 24, 2026, for personal reasons with no disagreement with the company. The board appointed Daniel Veikko Polvi as a new director on June 29, 2026, citing his extensive experience in business management and strategic consulting. No financial metrics or performance data were disclosed in this filing.

• · Ms. Huh confirmed she has been paid all amounts due and released the company from all claims.
• · Mr. Polvi holds an MBA from BI Norwegian Business School (June 2018) and has been managing director of Shearwater Limited since May 2019.
• · No family relationships exist between Mr. Polvi and any director or executive officer, and no reportable transactions under Item 404(a) were identified.

29-06-2026

Pinnacle West Capital Corp. approved a $1.5 million discretionary credit award for Adam Heflin, EVP and Chief Nuclear Officer of its subsidiary Arizona Public Service Company, to be credited in installments from 2026 to 2029 and vesting on May 1, 2030. The award is subject to continued employment and forfeiture upon early separation, except in cases of death, disability, or termination without cause. No negative or flat performance metrics were reported in this filing.

• · The award is granted under Section 3.9 of the Deferred Compensation Plan of 2005 for Employees of Pinnacle West Capital Corporation and Affiliates.
• · The account vests on May 1, 2030, contingent on continued employment through that date.
• · Forfeiture of unvested credits occurs upon separation from service before vesting, except for death, disability, or termination without cause.
• · Amounts in the account accrue interest per the Plan's terms.

29-06-2026

Columbia Financial, Inc. announced the appointment of four Northfield Bancorp directors to its board, effective upon completion of the pending merger. The board size was increased from nine to thirteen directors. The appointees bring extensive banking, accounting, and legal expertise, but no committee assignments were made at this time.

• · The appointments are subject to and effective upon completion of the merger.
• · None of the Northfield Continuing Directors were appointed to any committees of the Company’s Board of Directors at the time of appointment.
• · Columbia Bank's board size was also increased from 11 to 15 directors, effective at the Bank Merger effective time.
• · Steven M. Klein is a licensed CPA with over 35 years of banking and financial reporting experience, including SEC reporting.
• · Paul V. Stahlin is designated as an audit committee financial expert under SEC rules for Northfield.
• · The Merger Agreement was entered into on January 31, 2026, and involves a second-step conversion of the MHC prior to the merger.

29-06-2026

Synergy CHC Corp. held its 2026 annual meeting on June 29, 2026, where stockholders approved all five proposals, including the election of five directors, ratification of RBSM as auditor, an amendment to the 2024 Equity Incentive Plan to increase authorized shares to 150,000,000 and permit repricing, approval of share issuance upon exercise of the Lender Warrant, and a reverse stock split up to 1-for-200. However, the company's outstanding shares are only 14,899,883, and the proposed 150,000,000 share pool represents a massive 10x dilution, while the reverse split authorization signals potential Nasdaq compliance concerns.

• · Proposal 3 (Plan amendment) received 6,782,598 votes for, 860,297 against, 8,451 abstentions, and 2,156,773 broker non-votes.
• · Proposal 4 (Lender Warrant share issuance) received 7,327,670 votes for, 301,715 against, 21,961 abstentions, and 2,156,772 broker non-votes.
• · Proposal 5 (Reverse stock split) received 8,827,762 votes for, 969,208 against, and 11,148 abstentions, with no broker non-votes.
• · All director nominees received between 7,176,292 and 7,184,954 votes for, with 466,393 to 475,055 votes withheld, and 2,156,772 broker non-votes each.
• · Proposal 2 (RBSM ratification) passed with 9,808,117 votes for, 472,432 against, and 13,197 abstentions.

29-06-2026

Freedom Holding Corp. (Nasdaq: FRHC) announced the appointment of Valeriy Kim as Chief Financial Officer, succeeding Evgeny Ler, who served as CFO since 2015 and will transition to a special advisor role focusing on financing and M&A. Mr. Kim, previously Vice President of Finance and CEO of a subsidiary, brings experience from his prior CFO role at Freedom Finance Global PLC (2020-2024). The filing contains no financial data or period-over-period comparisons.

• · Evgeny Ler had served as CFO since 2015.
• · Valeriy Kim, age 37, previously served as CFO of Freedom Finance Global PLC from 2020 to 2024.
• · Both Kim and Ler began their careers at Deloitte before joining Freedom Holding Corp.

29-06-2026

Domtar Corporation elected David J. Johnson, Jr. as a director on June 26, 2026, following a consulting agreement with Gemsbok Partners LLC, where Mr. Johnson serves as Managing Member. Mr. Johnson brings over 25 years of legal and corporate finance experience from O'Melveny & Myers LLP, including senior leadership roles. No financial metrics or performance data were disclosed in this filing.

• · Mr. Johnson holds a J.D./M.B.A. from the University of Virginia School of Law/Darden School of Business and a B.A. in U.S. Government, with high honors, from the University of Virginia.
• · The consulting agreement with Gemsbok Partners LLC was dated April 7, 2026.
• · Mr. Johnson served as a member of the Policy Committee, Managing Partner of the Hong Kong office, Chair of the Transactions Department, and Co-Head of the Capital Markets Group at O'Melveny & Myers.

29-06-2026

ITT Inc. announced the election of Bertrand Loy and Kevin Wheeler to its Board of Directors, effective August 1, 2026. Loy brings public company CEO experience and global manufacturing expertise, while Wheeler adds deep industrial leadership and M&A experience. The appointments reflect ITT's disciplined board refreshment strategy, with Loy joining the Audit Committee and Wheeler joining the Nominating and Governance Committee.

• · Bertrand Loy served as CEO of Entegris from 2012 to 2025 and became Executive Chairman in 2025.
• · Kevin Wheeler served as CEO of A. O. Smith from 2018 to 2025 and became Executive Chairman in 2025, with over 30 years at the company.
• · Loy holds an MBA from ESSEC Business School in France; Wheeler holds a BS in Finance from the University of Nevada and completed the Advanced Management Program at Harvard Business School.
• · Loy was appointed to the Audit Committee; Wheeler was appointed to the Nominating and Governance Committee.

29-06-2026

United Therapeutics Corp held its 2026 Annual Meeting on June 26, 2026, where shareholders approved the 2026 Stock Incentive Plan, adding 1.5M new shares plus shares remaining from the prior plan (2,413,730) and shares subject to outstanding awards (4,941,655). All 12 director nominees were elected, and executive compensation was approved on an advisory basis. However, the 2026 Stock Incentive Plan received significant opposition with 10,070,290 votes against (28.0% of votes cast), indicating notable shareholder dissent.

• · Shareholder approval of executive compensation received 35,152,059 votes for and 1,048,505 against (2.9% against).
• · Ratification of Ernst & Young as auditor passed with 35,753,887 votes for and 1,647,415 against.
• · Director Kevin Tracey received the highest support with 36,187,554 votes for and only 18,239 against (0.05% against).
• · Director Christopher Causey received the lowest support with 32,342,983 votes for and 3,861,566 against (10.7% against).
• · Director Christopher Patusky also faced significant opposition with 32,649,292 votes for and 3,555,219 against (9.8% against).
• · The 2026 Plan replaces the Prior Plan; no further awards will be granted under the Prior Plan.

29-06-2026

TransAct Technologies appointed Troy Ingianni as CFO effective July 1, 2026, succeeding Steven DeMartino after Robert Campbell withdrew his candidacy for personal reasons. Ingianni brings over 25 years of financial leadership, most recently as VP, Global Controller and CAO at Barnes Group Inc., which was acquired for $3.6 billion. The appointment supports the company's focus on scaling its BOHA! SaaS platform and recurring revenue growth.

• · Robert Campbell, previously announced as successor to Steven DeMartino, withdrew his candidacy for personal reasons.
• · Troy Ingianni is a Certified Public Accountant in Connecticut and holds a Master of Science in Accounting and an MBA in Finance from the University of Connecticut.
• · Ingianni began his career at Pratt & Whitney as a Cost Analyst.
• · The filing includes extensive forward-looking risk factors related to economic conditions, supply chain, tariffs, and source code transition.

29-06-2026

Kayne DL 2021, Inc. announced the resignation of director Albert Rabil III on June 29, 2026. Rabil stepped down immediately as an 'interested' director due to his employment with Kayne Anderson Capital Advisors. His departure was not due to any disagreement with the company, and the board is now composed entirely of four independent directors.

• · Albert Rabil III was a Class III director whose term would have expired at the 2029 annual meeting if not reelected.
• · Rabil did not serve on any Board committees at the time of his resignation.
• · The Board now consists solely of Independent Directors, with no 'interested' persons under the 1940 Act.

29-06-2026

Kayne Anderson BDC, Inc. announced on June 29, 2026, that Albert Rabil III resigned from its Board of Directors effective immediately. Mr. Rabil, an “interested” director due to his ties to Kayne Anderson Capital Advisors, L.P., stated his resignation was not due to any disagreement with the Company. Following his departure, the Board now consists of six directors, with four being independent—maintaining a majority independent board.

• · Mr. Rabil's remaining term as Class III director would have expired at the 2029 annual meeting.
• · He did not serve on any Board committees at the time of his resignation.
• · The Company is not an emerging growth company.

29-06-2026

Tenax Therapeutics adopted a Change in Control Plan and Severance Plan for eligible employees on June 26, 2026, while simultaneously amending the employment agreements of CEO Christopher Giordano, Thomas Staab, and Stuart Rich to provide them with severance and change-in-control benefits generally aligned with those plans. The amendments include enhanced severance terms, such as 12 months of base salary plus additional months based on tenure for non-CIC terminations, and 18 months of base salary for Mr. Giordano in connection with a change in control. The executive officers are excluded from the new plans and remain covered by their individual amended agreements.

• · The CIC Plan provides 'double trigger' equity acceleration and cash severance benefits to eligible employees upon a qualifying termination within three months before or 12 months after a Change in Control.
• · The Severance Plan provides cash severance benefits to eligible employees terminated without Cause, independent of a change in control, based on tenure and level.
• · Benefits under both plans are conditioned on the eligible employee's execution of a release of claims.
• · For non-CIC terminations, each executive receives 12 months of base salary plus an additional month per completed year of service (up to 12 additional months), a pro-rated annual bonus at 100% goal achievement, and 12 months of COBRA reimbursements.
• · For CIC-related terminations, Mr. Giordano receives 18 months of base salary and 18 months of COBRA reimbursements, while Mr. Staab and Dr. Rich receive 12 months of base salary and 12 months of COBRA reimbursements.
• · Dr. Rich receives accelerated vesting of all outstanding equity awards in both non-CIC and CIC termination scenarios.

29-06-2026

American Eagle Outfitters held its 2026 Annual Meeting on June 26, 2026, where shareholders approved the re-election of Jay L. Schottenstein as Class I director, ratified Ernst & Young as auditor, approved advisory say-on-pay, and approved an amendment to the 2023 Stock Award and Incentive Plan increasing authorized shares by 9.68 million. The compensation proposal received strong support with 96.6% of votes cast in favor, while director Schottenstein received 86.9% support.

• · The A&R Plan extends the term from 2033 to 2036.
• · Broker non-votes were 12,071,823 for proposals 1, 3, and 4, and none for proposal 2.
• · Proposal 2 (ratification of EY) received 94.2% of votes cast in favor.

29-06-2026

Protara Therapeutics, Inc. announced the resignation of Leonardo Viana Nicacio, M.D., Chief Medical Officer, effective June 26, 2026, to pursue other opportunities. His duties will be assumed by Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, under the oversight of Jacqueline Zummo, Ph.D., Chief Research & Development Officer. No financial terms or compensatory arrangements were disclosed.

• · The resignation is effective June 26, 2026.
• · Dr. Nicacio's departure is to explore other opportunities.
• · Carla Beckham, M.D. will subsume Dr. Nicacio's duties as Lead Medical Director and Head of Clinical Development.
• · Jacqueline Zummo, Ph.D., Chief Research & Development Officer, will oversee clinical development.
• · No compensatory arrangements or financial details were disclosed in the filing.

29-06-2026

Corteva announced its intended board of directors for the future standalone crop protection company, with Greg Page as Independent Chair. The separation remains on track for Q4 2026. Luke Kissam will join the board as future CEO, while several existing directors will continue with Corteva.

• · Separation on track for Q4 2026.
• · Existing directors Karen Grimes, Marcos Lutz, Chuck Magro, and Kerry Preete will not continue with Corteva.
• · Luke Kissam appointed as future CEO and director effective at separation.
• · New board consists of 9 members.

29-06-2026

Cadrenal Therapeutics appointed John P. Sharp as Interim CFO via a services agreement with Lohman & Associates at $455/hour for up to 24 hours/week, replacing Quang X. Pham. Additionally, director Steven Zelenkofske resigned effective June 30, 2026, and the Board realigned its classes, moving Dr. Glynn Wilson from Class I to Class III. The company is searching for a permanent CFO.

• · Steven Zelenkofske's resignation was not due to any disagreement with the company.
• · Dr. Glynn Wilson was reappointed to the Audit Committee and Nominating and Corporate Governance Committee, and also appointed to the Compensation Committee.
• · The Master Services Agreement with Lohman & Associates was originally dated August 21, 2024.
• · L&A's services do not include tax advice or review/audit of financial statements.
• · Any services exceeding 24 hours per week require written approval from both parties.

29-06-2026

Swarmer, Inc. disclosed in an 8-K filing that its Board and Compensation Committee approved salary increases and new target bonuses for three top executives, effective retroactively to April 1, 2026. CEO (Global) Serhii Kupriienko and CEO (U.S.)/President Alexander Fink each received a 50% base salary increase from $250,000 to $375,000 and a target bonus of 100% of base salary. CFO Brooks Ensign received a 20% increase from $250,000 to $300,000 with a 50% target bonus. No financial results or declines were reported in this filing.

• · The salary increases were retroactively applied to April 1, 2026.
• · The Compensation Committee approved the changes on June 23, 2026.
• · The report was signed by Alexander Fink on June 29, 2026.
• · Swarmer, Inc is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

29-06-2026

Establishment Labs Holdings Inc. appointed Taylor Harris to its Board of Directors, effective June 29, 2026. Mr. Harris brings over 25 years of experience in corporate finance and executive leadership, having served as CEO of Cutera, CFO of MyoKardia (guiding its $13.1B acquisition by Bristol Myers Squibb), and CFO of Zeltiq Aesthetics and Thoratec. The appointment is expected to support the company's next phase of growth and shareholder value creation.

• · Taylor Harris currently serves on the board of Procept BioRobotics and previously served as a director of Omada Health and Endologix.
• · He spent more than a decade at JPMorgan Chase & Co. in healthcare equity research and investment banking.
• · Establishment Labs manufactures at two facilities in Costa Rica compliant with ISO13485:2024 and FDA 21 CFR 820.
• · The company has over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications.

29-06-2026

Fortune Brands Innovations appointed Jesse Singh as CEO effective June 29, 2026, succeeding interim CEO David Barry, who was named COO. Singh, former CEO of AZEK Company, brings over 30 years of experience in building products and manufacturing. The company also disclosed inducement awards of 850,000 performance-based RSUs and 300,000 stock options to Singh, and noted that its strategic review of the Fiberon business continues under Non-Executive Chair Susan Kilsby.

• · Singh's tenure at AZEK Company was from 2016 to 2025.
• · The Performance Award vests 50% on third anniversary and 50% on fourth anniversary of grant date, subject to stock price performance goals.
• · The Option Award vests in three equal installments on first three anniversaries of grant date.
• · Any shares received under inducement awards must be retained during employment; post-termination, at least 50% must be held for one year.
• · Interim CFO Ashley George continues in her role while the search for a permanent CFO continues.
• · Non-Executive Chair Susan Kilsby will directly oversee Fiberon operations during the strategic review.

29-06-2026

Tenaya Therapeutics appointed Eric Hyllengren as CFO effective July 13, 2026, succeeding Hiro Higa who will retire in Q3 2026 and remain as a consultant. Hyllengren brings over 20 years of biotech finance experience, including prior CFO roles at Zura Bio and Atara Biotherapeutics, where he executed over $500 million in public financings. The leadership transition comes as Tenaya advances two gene therapy programs (TN-201, TN-401) toward pivotal trials and a third candidate (TN-301) toward advancement, though no specific financial results or clinical milestones were disclosed in this filing.

• · Hiro Higa's retirement is unrelated to Hyllengren's hire; Higa will remain as a consultant through Q3 2026.
• · Hyllengren holds an MBA from Northwestern University's Kellogg School of Management and a BBA from the University of Notre Dame.
• · Higa contributed to Tenaya's financial infrastructure and guided the company through its IPO during his six-year tenure.

29-06-2026

Copart, Inc. announced that CEO Jeff Liaw will step down effective July 31, 2026, and Executive Chairman Jay Adair will resume the role of CEO. The transition is described as orderly, with Liaw staying on as Special Advisor. No financial metrics or performance declines were disclosed, but the filing highlights the company's strong operational position under Liaw's leadership.

• · Jeff Liaw served as CEO for approximately 10 years, previously as CFO and President.
• · Under Liaw, Copart achieved all-time high transaction values, average selling prices, and auction liquidity.
• · Copart was founded in 1982 and operates in 11 countries with over 250 locations.
• · Copart sold more than 4 million units in the last year and has approximately 1 million members in over 185 countries.

29-06-2026

MiniMed Group, Inc. expanded its Board from nine to 11 members, appointing David Endicott (CEO of Alcon) and Linnea Burman (SVP & President, Neurovascular at Medtronic) as directors effective June 29, 2026. The company also announced its 2026 Annual Meeting will be held virtually on October 9, 2026, with a record date of August 11, 2026, and set deadlines for stockholder proposals (July 26, 2026) and director nominations (July 17, 2026). No financial metrics or period-over-period comparisons were provided in this filing.

• · David Endicott will serve as a class I director with term expiring at the 2026 annual meeting and will sit on the Compensation and Talent Committee.
• · Linnea Burman will serve as a class II director with term expiring at the 2027 annual meeting.
• · While Medtronic is an affiliate of MiniMed, Ms. Burman will receive no compensation for her board service; thereafter, compensation will match other non-employee directors.
• · The 2026 Annual Meeting will be held virtually on Friday, October 9, 2026 at 9:00 a.m. Pacific Time.
• · Record date for the 2026 Annual Meeting is August 11, 2026.
• · Stockholder proposals under Rule 14a-8 must be received by July 26, 2026.
• · Director nominations and other business proposals must be received by July 17, 2026.